A detailed history of High Point Advisor Group LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, High Point Advisor Group LLC holds 20,035 shares of LLY stock, worth $15.9 Million. This represents 1.06% of its overall portfolio holdings.

Number of Shares
20,035
Previous 21,054 4.84%
Holding current value
$15.9 Million
Previous $19.1 Million 6.88%
% of portfolio
1.06%
Previous 1.08%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$772.14 - $960.02 $786,810 - $978,260
-1,019 Reduced 4.84%
20,035 $17.7 Million
Q2 2024

Aug 08, 2024

BUY
$724.87 - $909.04 $2.84 Million - $3.56 Million
3,918 Added 22.86%
21,054 $19.1 Million
Q1 2024

May 14, 2024

BUY
$592.2 - $792.28 $112,518 - $150,533
190 Added 1.12%
17,136 $13.3 Million
Q4 2023

Mar 26, 2024

BUY
$525.19 - $619.13 $2.82 Million - $3.32 Million
5,367 Added 46.35%
16,946 $9.88 Million
Q2 2022

Aug 15, 2022

BUY
$278.73 - $327.27 $164,171 - $192,762
589 Added 5.36%
11,579 $3.82 Million
Q3 2021

Nov 15, 2021

SELL
$221.6 - $272.71 $200,991 - $247,347
-907 Reduced 7.62%
10,990 $2.54 Million
Q2 2021

Jul 29, 2021

BUY
$180.55 - $233.54 $419,959 - $543,214
2,326 Added 24.3%
11,897 $2.73 Million
Q1 2021

Apr 12, 2021

BUY
$164.32 - $212.72 $112,723 - $145,925
686 Added 7.72%
9,571 $1.77 Million
Q4 2020

Feb 10, 2021

BUY
$130.46 - $172.63 $75,666 - $100,125
580 Added 6.98%
8,885 $1.79 Million
Q3 2020

Nov 06, 2020

SELL
$146.22 - $169.13 $47,521 - $54,967
-325 Reduced 3.77%
8,305 $1.21 Million
Q2 2020

Aug 13, 2020

SELL
$136.42 - $164.18 $26,738 - $32,179
-196 Reduced 2.22%
8,630 $1.41 Million
Q1 2020

May 01, 2020

BUY
$119.05 - $147.35 $879,541 - $1.09 Million
7,388 Added 513.77%
8,826 $1.44 Million
Q1 2020

Apr 27, 2020

SELL
$119.05 - $147.35 $925,494 - $1.15 Million
-7,774 Reduced 84.39%
1,438 $8.83 Million
Q4 2019

Feb 13, 2020

BUY
$106.92 - $132.43 $68,963 - $85,417
645 Added 7.53%
9,212 $1.3 Million
Q3 2019

Nov 12, 2019

BUY
$106.79 - $116.16 $103,159 - $112,210
966 Added 12.71%
8,567 $972,000
Q2 2019

Aug 15, 2019

SELL
$110.79 - $129.32 $253,709 - $296,142
-2,290 Reduced 23.15%
7,601 $815,000
Q1 2019

May 08, 2019

SELL
$111.31 - $131.02 $60,552 - $71,274
-544 Reduced 5.21%
9,891 $1.14 Million
Q4 2018

Feb 20, 2019

BUY
$105.9 - $118.64 $261,573 - $293,040
2,470 Added 31.01%
10,435 $1.27 Million
Q3 2018

Oct 24, 2018

BUY
$85.86 - $107.31 $12,277 - $15,345
143 Added 1.83%
7,965 $892,000
Q2 2018

Aug 20, 2018

SELL
$75.7 - $86.88 $52,535 - $60,294
-694 Reduced 8.15%
7,822 $816,000
Q1 2018

Jun 11, 2018

BUY
$74.21 - $87.6 $30,871 - $36,441
416 Added 5.14%
8,516 $733,000
Q4 2017

Feb 15, 2018

BUY
$81.94 - $87.89 $19,010 - $20,390
232 Added 2.95%
8,100 $617,000
Q3 2017

Nov 06, 2017

BUY
$77.07 - $85.54 $606,386 - $673,028
7,868
7,868 $654,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $756B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track High Point Advisor Group LLC Portfolio

Follow High Point Advisor Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Point Advisor Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Point Advisor Group LLC with notifications on news.